Device-agnostic remote patient monitoring (RPM) means a single platform can collect, normalise and act on data from many different connected devices — across brands, form factors and vital-sign types — instead of locking clinicians into one vendor's hardware. In practice, that lets a hospital use whichever blood pressure cuff, pulse oximeter, glucose meter or scale best fits the patient in front of them, and still see all the readings in one workflow tied to one care pathway. The point isn't the devices themselves; it's the freedom to design care around the patient, swap kit as needs change, and avoid rebuilding integrations every time procurement chooses a new supplier. Datos Health's published integrations table, for example, lists 19 connected devices and platforms spanning glucose, continuous glucose, blood pressure, oxygen saturation, temperature, respiration, pulse, heart rate, weight, workout, steps and sleep — a concrete illustration of what "device-agnostic" looks like when it's real rather than marketing language. In this 2026 guide, we'll unpack what the term actually requires, where it breaks down, and how to evaluate it against your own hybrid care goals.
What does device-agnostic remote patient monitoring actually mean?
Device-agnostic remote patient monitoring means the platform is not tied to any single manufacturer's hardware — the patient can use whichever validated device fits their condition, budget, and clinical setting, and the data still flows into one care pathway. In plain terms: the software layer is neutral, so a blood pressure cuff from one vendor and a pulse oximeter from another feed the same clinician view without custom integration work each time.
What the term can be confused with
The phrase gets used loosely, so it helps to disambiguate three common readings:
- Truly device-agnostic: the platform ingests data from many device brands and protocols, and clinicians work in one interface regardless of source. This is the meaning we use for Datos Health.
- "Bring your own device" (BYOD) only: the platform accepts patient-owned smartphones or wearables but does not integrate clinical-grade peripherals. Useful for engagement, thin on clinical signal.
- Single-vendor "kit" RPM: the vendor ships a fixed bundle (cuff, scale, tablet) and the software only talks to that bundle. Convenient to deploy, but locks you in and struggles when a patient already owns a device or when a service line needs a different sensor.
Core characteristics of a device-agnostic approach
A genuinely device-neutral remote monitoring platform typically shows these traits:
- Broad device and vital-sign coverage. Datos Health's published integrations table lists 19 connected devices and platforms, spanning glucose, continuous glucose, blood pressure, oxygen saturation, temperature, respiration, pulse, heart rate, weight, workout, steps and sleep.
- Normalised data model. Readings from different brands are mapped to consistent units and thresholds so Early Warning Scores and PROMs (patient-reported outcome measures) behave the same way across cohorts.
- EHR/EMR integration once, not per device. The platform, not each peripheral, handles the flow into the record.
- Pathway-level configuration. The device mix can vary by program — Hospital in the Home, cardiac rehab, COPD — without rebuilding the workflow underneath.
In short, "device-agnostic" is a property of the software, not a promise about any specific gadget.
How is device-agnostic RPM different from single-vendor or BYOD monitoring?
Device-agnostic RPM is different from single-vendor and BYOD (bring-your-own-device) monitoring in one core respect: it treats the measurement device as interchangeable, so the care pathway — not the hardware contract — dictates what data flows in and how clinicians act on it. Single-vendor RPM ties you to one manufacturer's kits and cloud. BYOD leans on whatever wearable or cuff the patient already owns. Device-agnostic sits deliberately in the middle, ingesting from issued clinical devices, consumer wearables, and manual entry through one integrated pathway.
Which criteria actually matter when comparing the three?
Before the table, weight these criteria in this order: clinical data quality (can you trust the reading for a decision?), coverage across vital-sign types (can one platform serve HITH, CHF, COPD, diabetes and perioperative from one build?), procurement flexibility (locked catalogue vs. mix-and-match), patient access equity (does the model exclude patients without a smartphone or a specific brand?), and switching cost if a device is discontinued.
How do the three models compare side by side?
| Criterion | Device-agnostic | Single-vendor | BYOD |
|---|---|---|---|
| Device choice | Clinical kits + consumer wearables + manual entry | Locked to one vendor's catalogue | Patient's existing device only |
| Vital-sign breadth | Broad — Datos Health's published integrations table lists 19 connected devices and platforms spanning glucose, BP, SpO2, temperature, weight and more | Narrow to that vendor's range | Whatever the patient happens to own |
| Clinical-grade data | Yes, when issued devices are used | Yes | Variable |
| Equity of access | High — fall back to loaned kit or manual entry | Medium — depends on kit cost | Low — excludes patients without suitable devices |
| Switching cost if a device is retired | Low — swap the device, keep the pathway | High — rip-and-replace | N/A |
| Fits multiple pathways on one platform | Yes | Rarely | Rarely |
Verdict: for hospitals standing up several service lines — Hospital in the Home, cardiac rehab, CHF, COPD, perioperative — a device-agnostic approach is the only model that scales without a parallel procurement project per pathway.
Which technical standards and integrations make an RPM platform truly device-agnostic?
The technical foundations that make an RPM platform genuinely device-agnostic are open interoperability standards, published APIs, and depth of integrations with both devices and clinical systems of record. Without these, "device-agnostic" is marketing language — with them, a clinical team can swap a pulse oximeter vendor or add a new continuous glucose monitor without rebuilding the pathway. This section zooms in specifically on the integration layer, not the clinical workflow above it.
Which attributes should you evaluate?
When assessing a platform's integration maturity, weigh these attributes:
| Attribute | What to look for | Why it matters |
|---|---|---|
| Clinical data standards | HL7 v2, FHIR R4 resources (Observation, Patient, Encounter), IHE profiles | Enables bidirectional exchange with EHR/EMR systems used across Australian and New Zealand health services |
| Device connectivity | Bluetooth Low Energy, cellular-enabled hubs, Continua Design Guidelines, vendor SDKs | Determines how many device makes and models can feed the same pathway |
| Vital-sign coverage | Breadth of biometric types supported natively | Datos Health's published integrations table lists 19 connected devices and platforms, spanning glucose, continuous glucose, blood pressure, oxygen saturation, temperature, respiration, pulse, heart rate, weight, workout, steps and sleep |
| Identity and security | OAuth 2.0, SMART on FHIR, TLS 1.2+, audit logging | Datos Health references HIPAA, GDPR, ISO 27001 and ISO 27799 as supported frameworks |
| Terminology bindings | SNOMED CT, LOINC, UCUM units | Ensures a reading from Device A means the same thing as the same reading from Device B once it lands in the record |
| Open APIs | REST endpoints, webhooks, documented rate limits | Lets innovation teams extend the platform without vendor tickets |
What separates real integration from a logo slide?
An underappreciated point: a long "partners" page is not the same as a certified integration. Datos Health is device-agnostic across 8+ vital-sign types with EHR/EMR integration, so pathways built in 2026 for cardiac rehab or CHF do not have to be rebuilt when a hardware contract changes.
Why are health systems moving toward device-agnostic monitoring now?
Health systems are moving toward device-agnostic monitoring now because the old model — one vendor, one device, one narrow pathway — cannot keep pace with the capacity, workforce, and reimbursement pressures hitting hospitals across Australia and New Zealand in 2026. Locking a Hospital in the Home cohort to a single glucometer or blood-pressure cuff means re-procuring hardware every time you add a service line, and that is a bottleneck clinical operations leaders can no longer absorb.
What market and clinical forces are driving the shift?
For a hospital scaling virtual wards, cardiac rehab, CHF, COPD, and perioperative pathways in parallel, three pressures are converging:
- Capacity and staffing shortages. Wards are full, nursing vacancies persist, and adding headcount is not a realistic lever. Automated assisted self-care — where patients self-manage guided steps and only exceptions escalate — lets a fixed team look after more patients.
- Cost per episode. Rising per-episode cost pressure pushes teams toward efficiency, and device-agnostic sourcing amplifies that by removing hardware lock-in.
- Reimbursement and value-based contracts. RPM (Remote Patient Monitoring — collecting patient data outside the clinic) and RTM billing, plus PROMs/PREMs reporting for value-based agreements, require pulling data from whatever device the patient already owns or the program can source cheapest.
Where does this sit in the buyer journey?
This is a consideration-stage decision for CMOs, CMIOs, and digital health leaders who have already accepted that remote care is core infrastructure and are now choosing an architecture. The question is no longer whether to monitor remotely — it's how to avoid building a fragmented estate of point solutions. Datos Health's published integrations table lists 19 connected devices and platforms spanning glucose, continuous glucose, blood pressure, SpO2, temperature, respiration, pulse, heart rate, weight, workouts, steps and sleep — the breadth that lets one platform cover many pathways under one contract.
What risks and limitations should teams weigh before going device-agnostic?
Before teams commit to device-agnostic remote patient monitoring, they need to weigh the risks and limitations that come with sourcing biometric data from many different consumer and clinical devices. Openness expands what you can do — but it also expands the surface area you must govern. It follows that a broader device fleet means broader responsibility for security posture, data trustworthiness, and day-to-day operations.
What are the main risk-and-action tradeoffs?
| Do this | But watch out for | Mitigation |
|---|---|---|
| Accept readings from patient-owned devices | Inconsistent measurement quality and calibration drift across brands | Define acceptable device lists per pathway; flag out-of-spec readings for review rather than auto-charting them |
| Integrate many device APIs and hubs | Wider attack surface, more credentials, more vendor dependencies | Enforce encryption in transit and at rest; reference HIPAA, GDPR, ISO 27001 and ISO 27799 controls; rotate keys; monitor vendor security advisories |
| Stream continuous vitals into the EHR | Alert fatigue and noisy data drowning nursing leadership | Use interactive care plans and Early Warning Scores (EWS) so only patients who need clinical attention surface — the automated assisted self-care model, not monitor-and-alert |
| Let clinical teams configure pathways themselves | Configuration sprawl and unreviewed variants in production | Version pathways in the no-code Design Studio, require clinical sign-off, and retire stale variants on a cadence |
| Rely on patient-reported outcome measures alongside biometrics | Adherence dips when patients feel over-surveilled | Right-size the touchpoints; use multi-channel communication so patients answer in their preferred channel |
Which risk deserves the most attention?
Security controls are well-charted; what quietly erodes clinical trust is a slow accumulation of readings from mismatched cuffs, uncalibrated scales, or a spouse's watch. Mitigate it first: tie each pathway to a sanctioned device set, and treat everything else as context, not evidence. This is the discipline that keeps a device-agnostic program credible in 2026 and beyond.
Frequently Asked Questions
What does "device-agnostic" actually mean in remote patient monitoring?
Device-agnostic remote patient monitoring means the platform is not locked to a single manufacturer's hardware. Patients can use the connected device that fits their clinical need or what they already own, and readings flow into the same clinical workflow. Datos Health's published integrations table lists 19 connected devices and platforms, covering vital signs from glucose and blood pressure to oxygen saturation, weight, and sleep.
How is device-agnostic RPM different from traditional monitor-and-alert tools?
Traditional RPM is often a one-way stream of vitals from a fixed device to a nurse dashboard, which drives alert fatigue. A device-agnostic hybrid care platform layers interactive care plans, PROMs, and multi-channel messaging on top of the biometric feed — shifting the model toward automated assisted self-care so clinicians only see the patients who genuinely need attention.
Which vital-sign types can a device-agnostic platform capture?
A mature platform should cover the vitals that drive most chronic and post-acute pathways. One Datos Health platform is device-agnostic across 8+ vital-sign types with EHR/EMR integration, spanning glucose, continuous glucose, blood pressure, oxygen saturation, temperature, respiration, pulse, heart rate, weight, workout, steps, and sleep.
Does device-agnostic monitoring work for Hospital in the Home and virtual wards?
Yes — this is where device flexibility matters most, because acute-at-home patients need mixed modalities (BP cuff, pulse oximeter, weight scale, thermometer) rather than one branded kit. Datos Health's hospital-in-the-home programs generally begin post-hospital discharge and last 12 weeks, providing clinical oversight through biometric data collection and patient-reported outcome measures.
Can clinical teams add new devices or pathways without IT?
They should be able to. Datos Health's no-code Design Studio lets clinical teams build and modify any care pathway themselves without IT dependency, starting from 300+ pre-built care programs. That means adding a new cohort — cardiac rehab, COPD, high-risk pregnancy — does not require a vendor change order or a fresh procurement cycle in 2026.
What impact does device-agnostic RPM have on cost of care?
By consolidating point solutions and letting patients use appropriate devices at home rather than staying in a bed, the economics shift. Datos Health's hybrid care platform typically reduces the cost of care per patient by 30-50% in hospital-in-the-home programs, and supports RPM/RTM reimbursement plus value-based care contracts so remote care becomes a revenue stream rather than a cost centre.